GSA Capital Partners LLP Invests $235,000 in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

GSA Capital Partners LLP acquired a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,873 shares of the company’s stock, valued at approximately $235,000.

A number of other institutional investors also recently added to or reduced their stakes in HRMY. nVerses Capital LLC purchased a new position in Harmony Biosciences in the second quarter worth $36,000. CWM LLC increased its holdings in shares of Harmony Biosciences by 111.7% in the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares in the last quarter. Quarry LP acquired a new stake in shares of Harmony Biosciences in the second quarter valued at about $62,000. Headlands Technologies LLC boosted its holdings in Harmony Biosciences by 1,608.1% during the second quarter. Headlands Technologies LLC now owns 2,545 shares of the company’s stock worth $77,000 after buying an additional 2,396 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Harmony Biosciences by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after buying an additional 360 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $34.07 on Monday. The company’s fifty day simple moving average is $35.53 and its 200-day simple moving average is $33.56. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 52 week low of $28.14 and a 52 week high of $41.61. The company has a market cap of $1.94 billion, a PE ratio of 16.15, a P/E/G ratio of 0.62 and a beta of 0.77.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.15. The company had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter last year, the company earned $0.63 earnings per share. As a group, equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.

Insider Buying and Selling at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 21,496 shares of the business’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total value of $869,943.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 30.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on HRMY shares. UBS Group assumed coverage on Harmony Biosciences in a research note on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price objective for the company. Raymond James restated an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 10th. Oppenheimer reissued an “outperform” rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a report on Tuesday, October 29th. Finally, Mizuho upped their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Harmony Biosciences currently has an average rating of “Moderate Buy” and an average target price of $47.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.